Leerink Partners Upgrades Abbott Laboratories to Outperform From In Line
Leerink Partners upgraded Abbott Laboratories to Outperform from In Line and set a $124 price target.
Leerink Partners upgraded Abbott Laboratories to Outperform from In Line and set a $124 price target.